Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable discussed the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
Real-World Experiences and Evidence
The discussion highlighted real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies.
Stewart, MD, summarized the key takeaways from the discussion.
Stewart, a professor and chairman emeritus of ophthalmology at Mayo Clinic in Jacksonville, Florida, described a case of an 83-year-old woman with diabetic macular edema (DME).
- She had undergone temporal grid laser photocoagulation for macular edema.
- She received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Author's summary: Anti-VEGF agents improve retinal disease treatment.
More News
- Newest Ted's Fish Fry coming to Ballston Spa
- Porsche’s 99% Profit Tumble Signals Trouble for Luxury Brands Worldwide
- Sinners: blood, blues and vampires - The Stute
- Maria Becerra’s Sultry ‘JOJO’ & More Best New Music Latin
- Can Joji, Tame Impala or Chris Brown & Usher Make Waves on the Hot 100 Next Week? | The Contenders